AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05694637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
Study NCT05636137 — intervention group
Intervention type: OTHER
Intervention: Survey application
Description: Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
Study NCT05561075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pterostilbene cocrystal
Description: One capsule with Pterostilbene cocrystal
Study NCT05834582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Paclitaxel
Description: Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
Study NCT05834582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin+Cyclophosphamide
Description: Epirubicin+Cyclophosphamide
Study NCT05561075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pterostilbene free form
Description: One capsule with Pterostilbene free form
Study NCT04670653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNÓLIA NASAL GEL
Description: Magnólia nasal gel spray
Study NCT04670653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOMETASONE FUROATE
Description: Mometasone furoate nasal spray
Study NCT06408194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22CART infusion
Description: CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
Study NCT06408194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin/Relebactam
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Given IV
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Given IV or PO
Study NCT04983901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Given IV or PO
Study NCT06471166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Amh hormone
Description: Ovarian reserve
Study NCT05383950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone application
Description: In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory, cardiac, or geriatric diseases.
Study NCT06111547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 oral tablet.
Study NCT06111547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.
Study NCT05228457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive intermittent theta-burst stimulation (iTBS)
Description: Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
Study NCT05228457 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intensive intermittent theta-burst stimulation (iTBS)
Description: Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
Study NCT06272214 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area.
Study NCT06272214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
Study NCT05638880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Description: Valsartan is an angiotensin receptor blocker.
Study NCT05638880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Valsartan is an angiotensin receptor blocker.
Study NCT05638880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin is an oral hypoglycemic drug.
Study NCT05638880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin is an oral hypoglycemic drug.
Study NCT05638880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: Levocetirizine, Histamine-1 receptor antagonists provide a highly successful approach for controlling allergic and inflammatory conditions
Study NCT06301659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation therapy
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
Study NCT06301659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation therapy
Description: The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
Study NCT06301659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified mirror therapy
Description: The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
Study NCT05124249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
Description: Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment
Study NCT05124249 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: Patients who undergoing PCI
Study NCT06126445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battery operated toothbrush
Description: Device on plaque removal efficacy
Study NCT06126445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: Device on plaque removal efficacy
Study NCT04855877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tablet
Description: Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
Study NCT04855877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of lactose tablet (placebo)
Study NCT05951127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Esophagectomy for esophageal cancer and regional lymph nodes dissection.
Study NCT04913805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate
Description: Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
Study NCT04913805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
Description: Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside will be used as a combination intervention to both increase blood flow (KNO3) and mitochondrial function (PLC + NR)
Study NCT04913805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride
Description: Active control
Study NCT05508568 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ADXBLADDER
Description: ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
Study NCT05372705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
Study NCT06512428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simmitinib plus irinotecan liposome
Description: simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
Study NCT06512428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome
Description: irinotecan liposome 70 mg/m\^2 every 2 weeks
Study NCT06512428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan 180mg/m\^2 every 2 weeks
Study NCT03954327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
Description: Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
Study NCT03954327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir (RTF) 600 mg two tablets by mouth once per day
Study NCT03954327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule [CEBOCAP]
Description: Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
Study NCT05698628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal perfusion catheterization
Description: Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
Study NCT05436340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Effect Of Heel Protector In Intensive Care Units
Description: In the experimental group, foot joint opening and heel pressure sore formation will be observed by using heel protector pad.
Study NCT06452030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific sensorimotor control training
Description: Participants allocated to the specific motor control group will receive sensorimotor training of the multifidus muscle.
Study NCT06452030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aspecific extension training
Description: Participants allocated to the aspecific group will receive spinal extension exercises.
Study NCT06452030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fascia training
Description: Participants allocated to the fascia group will receive general movement exercises.
Study NCT05436340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Heel pads will not be used in the control group. Routine maintenance will be applied
Study NCT05818111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroid
Description: triamcinolone 40mg 4cc
Study NCT05818111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid
Description: triamcinolone 40mg 4cc
Study NCT05698628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal perfusion catheterization
Description: Distal perfusion catheterization will be done within 1 hour after the VA-ECMO application in the preemptive DPC group. The conventional DPC group will undergo distal perfusion catheterization at the time of limb ischemia sign.
Study NCT05437068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement (ONS)
Description: ONS plus dietary counseling
Study NCT05815667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualised Active Communication Education (I-ACE)
Description: The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
Study NCT04895553 — intervention group
Intervention type: OTHER
Intervention: Observation of ICH and VTE
Description: The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
Study NCT05818111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine 2 % Injectable Solution
Description: xylocaine 2% 4cc
Study NCT05818111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 2 % Injectable Solution
Description: xylocaine 2% 4cc
Study NCT05818111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline 2cc
Description: normal saline 2cc
Study NCT05818111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline 12cc
Description: normal saline 12cc
Study NCT06206070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Hong Kong version of Westmead Feeling Program 2
Description: Westmead Feelings Program (WFP) is a manualized emotion-based learning intervention for children on the autism spectrum. WFP teaches autistic children how to understand their own and other's emotions, solve problems, and regulate emotions through the implementation of transactional support. In doing so, parents and teachers are also trained to develop their emotional coaching skills to support children in everyday settings. Its impact on improving emotional competence in primary school-aged children on the autism spectrum has been established in 41 mainstream schools in Australia.
Study NCT06309407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Dosimeters
Description: Participants were assigned to wear hand dosimeters in addition to the standard chest dosimeter worn by all participants
Study NCT06309407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Participants only wore standard chest dosimeters
Study NCT04650854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Study NCT04859114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
Study NCT04859114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Format of outcome data presentation
Description: Outcome data is provided to participants as either text-only, a static pictograph, or an iterative pictograph.
Study NCT05557474 — intervention group
Intervention type: OTHER
Intervention: Early-stage lung cancer prognostic kit -- ELISA
Description: blood sample with ELISA
Study NCT05557474 — intervention group
Intervention type: OTHER
Intervention: Early-stage lung cancer prognostic kit -- IHC
Description: surgical tumor part with IHC
Study NCT05616234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
Study NCT04634162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study NCT04634162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cangrelor
Description: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study NCT04634162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study NCT04634162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Study NCT05067660 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.
Study NCT05067660 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Current standard template-based salvage therapy
Description: In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
Study NCT05331365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests
Description: Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8